Published in Vasc Health Risk Manag on January 01, 2008
What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? Cardiovasc Diabetol (2012) 0.88
Efficacy and tolerability of fixed dose combination of metoprolol and amlodipine in Indian patients with essential hypertension. J Midlife Health (2013) 0.84
Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors. Integr Blood Press Control (2009) 0.83
Bioequivalence evaluation of two amlodipine salts, besylate and orotate, each in a fixed-dose combination with olmesartan in healthy subjects. Drug Des Devel Ther (2015) 0.78
Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals. Integr Blood Press Control (2010) 0.75
Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes. Integr Blood Press Control (2010) 0.75
Combination of anti-hypertensive drugs: a molecular dynamics simulation study. J Mol Model (2017) 0.75
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 40.37
Global burden of hypertension: analysis of worldwide data. Lancet (2005) 32.76
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2007) 22.81
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 18.15
Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA (2003) 14.77
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet (2003) 12.67
Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension (2006) 11.68
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13
Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA (1993) 6.27
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA (1967) 5.54
Preventable causative factors leading to hospital admission with decompensated heart failure. Heart (1998) 4.92
Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med (1996) 4.25
Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med (2007) 4.20
Impact of dosage frequency on patient compliance. Diabetes Care (1997) 2.43
Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Arch Intern Med (2007) 2.34
Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation (2004) 1.81
Calcium-antagonist drugs. N Engl J Med (1999) 1.78
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension (2006) 1.71
Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens (2004) 1.60
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) (2001) 1.59
Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J (1995) 1.51
Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs (2002) 1.41
Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem (2006) 1.38
Drug compliance among hypertensive patients in Tabuk, Saudi Arabia. J Hypertens (1997) 1.31
Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol (1997) 1.26
Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail (2003) 1.20
Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol (2001) 1.16
Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press (2007) 1.15
Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol (2007) 1.12
Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens (2005) 1.08
Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. A large multicenter study. Lisinopril-Hydrochlorothiazide Group. Arch Intern Med (1994) 1.00
The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl (2001) 0.97
Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens (2001) 0.96
Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens (Greenwich) (2005) 0.95
The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens (Greenwich) (2004) 0.93
Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol (2001) 0.91
Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy? Drugs (1994) 0.89
Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) (2007) 0.88
Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Curr Hypertens Rep (2000) 0.88
Medication noncompliance: what is the problem? Manag Care (2000) 0.87
Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens (2005) 0.87
Issues in patient compliance. Drugs (1997) 0.86
Critical assessment of calcium antagonists. Aust Fam Physician (1997) 0.81
Evolution of calcium antagonists: past, present, and future. Clin Cardiol (2003) 0.80
More medications, fewer pills: combination medications for the treatment of hypertension. Can J Cardiol (2007) 0.78
Effects of amlodipine and lisinopril on left ventricular mass and diastolic function in previously untreated patients with mild to moderate diastolic hypertension. Blood Press (1998) 0.76
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation (2011) 5.26
The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension (2011) 5.14
Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension (2009) 4.26
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation (2007) 4.16
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78
Evidence-based guidelines for cardiovascular disease prevention in women. Circulation (2004) 3.39
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. J Am Coll Cardiol (2011) 2.89
Blood pressure measurement device, number and timing of visits, and intra-individual visit-to-visit variability of blood pressure. J Clin Hypertens (Greenwich) (2012) 2.85
Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension (2013) 2.83
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 2.69
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens (Greenwich) (2013) 2.64
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol (2003) 2.47
Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med (2015) 2.42
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res (2007) 2.32
Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) (2011) 2.11
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med (2003) 2.09
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol (2009) 2.01
Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov (2002) 1.98
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation (2011) 1.97
Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest (2013) 1.88
Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension (2010) 1.85
Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension (2009) 1.82
Estrogen modulates TNF-alpha-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation. Am J Physiol Heart Circ Physiol (2007) 1.80
Sex hormones and hypertension. Cardiovasc Res (2002) 1.74
Trends in hypertension prevalence, awareness, treatment, and control among US adults 80 years and older, 1988-2010. J Clin Hypertens (Greenwich) (2014) 1.72
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol (2007) 1.69
Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med (2008) 1.68
Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol (2012) 1.66
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol (2012) 1.62
Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension (2003) 1.61
Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol (2004) 1.59
Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes (2012) 1.59
Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens (2007) 1.54
Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. Am J Physiol Heart Circ Physiol (2008) 1.53
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens (2004) 1.53
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension (2004) 1.52
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation (2011) 1.52
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens (2002) 1.51
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension (2005) 1.49
Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement. Arterioscler Thromb Vasc Biol (2004) 1.49
Phosphatidylinositol-3-kinase signaling mediates vascular smooth muscle cell expression of periostin in vivo and in vitro. Atherosclerosis (2005) 1.48
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens (2009) 1.48
Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension (2008) 1.46
Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Soc Hypertens (2015) 1.45
Transforming growth factor-beta signaling mediates hypoxia-induced pulmonary arterial remodeling and inhibition of alveolar development in newborn mouse lung. Am J Physiol Lung Cell Mol Physiol (2008) 1.45
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension (2008) 1.44
Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status. J Hypertens (2016) 1.43
Salt sensitivity, a determinant of blood pressure, cardiovascular disease and survival. J Am Coll Nutr (2006) 1.41
Hypoxia-responsive growth factors upregulate periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells. J Appl Physiol (1985) (2004) 1.31
Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens (2004) 1.30
Prehypertension: epidemiology, consequences and treatment. Nat Rev Nephrol (2009) 1.28
Combination therapy in hypertension. J Am Soc Hypertens (2010) 1.28
Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury. Am J Physiol Heart Circ Physiol (2008) 1.26
Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries. Circulation (2004) 1.26
Dominant negative mutation of the TGF-beta receptor blocks hypoxia-induced pulmonary vascular remodeling. J Appl Physiol (1985) (2005) 1.25
Reproducibility of visit-to-visit variability of blood pressure measured as part of routine clinical care. J Hypertens (2011) 1.23
Association between antihypertensive medication adherence and visit-to-visit variability of blood pressure. J Clin Hypertens (Greenwich) (2012) 1.21
Adherence and persistence with taking medication to control high blood pressure. J Am Soc Hypertens (2011) 1.20
Loss of Thy-1 inhibits alveolar development in the newborn mouse lung. Am J Physiol Lung Cell Mol Physiol (2009) 1.19
Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling. Pediatr Res (2005) 1.17
Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. Circulation (2003) 1.16
Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med (2010) 1.15
Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol (2015) 1.15
Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension (2007) 1.14
Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Am J Physiol Lung Cell Mol Physiol (2011) 1.12
O-GlcNAc modification of NFκB p65 inhibits TNF-α-induced inflammatory mediator expression in rat aortic smooth muscle cells. PLoS One (2011) 1.11
Role of matrix metalloproteinase-2 in newborn mouse lungs under hypoxic conditions. Pediatr Res (2008) 1.10
Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent. Am J Pathol (2007) 1.10
Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich) (2012) 1.10
Atrial natriuretic peptide-dependent modulation of hypoxia-induced pulmonary vascular remodeling. Life Sci (2006) 1.08
Less-tight versus tight control of hypertension in pregnancy. N Engl J Med (2015) 1.07
Secondary prevention of coronary heart disease in women: a call to action. Ann Intern Med (2003) 1.07
Reply to Visit-to-visit blood pressure variation: time to reanalyze all the data from the TROPHY study. J Clin Hypertens (Greenwich) (2013) 1.06
Role of oxygen availability in CFTR expression and function. Am J Respir Cell Mol Biol (2008) 1.05
Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation (2002) 1.05
ANP signaling inhibits TGF-beta-induced Smad2 and Smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells. J Appl Physiol (1985) (2006) 1.05
Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling. Hypertension (2004) 1.05
When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens (2010) 1.04
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich) (2011) 1.04
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. Blood Press (2004) 1.04
ASH Position Paper: Dietary approaches to lower blood pressure. J Clin Hypertens (Greenwich) (2009) 1.03
Inhibition of transforming growth factor-beta signaling induces left ventricular dilation and dysfunction in the pressure-overloaded heart. Am J Physiol Heart Circ Physiol (2009) 1.01
Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. Menopause (2007) 1.01
Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol (2013) 0.99
Pressure-independent enhancement of cardiac hypertrophy in atrial natriuretic peptide-deficient mice. Clin Exp Pharmacol Physiol (2003) 0.98
Management of hypertension in the elderly. Nat Rev Cardiol (2012) 0.98